Volume 16, Number 9—September 2010
Dispatch
KI and WU Polyomaviruses and CD4+ Cell Counts in HIV-1–infected Patients, Italy
Muhammed Babakir-Mina, Massimo Ciccozzi, Francesca Farchi, Massimiliano Bergallo, Rossana Cavallo, Gaspare Adorno, Carlo Federico Perno, and Marco Ciotti
Table 2
Treatment regimens for 11 HIV-1–positive patients co-infected with KI or WU polyomavirus, Italy, 2004–2009*
| Patient no. | KIPyV | WUPyV | HAART |
|---|---|---|---|
| 1 | + | – | None |
| 2 | + | – | None |
| 3 | + | – | None |
| 4 | + | – | NRTI: FTC, TDF; PI: ATV, RTV |
| 5 | – | + | NNRTI: EFV; NRTI: 3TC, TDF |
| 6 | – | + | NNRTI: NVP; NRTI: 3TC, AZT |
| 7 | – | + | NRTI: 3TC, AZT; PI: ATV, RTV |
| 8 | – | + | NNRTI: NVP; NRTI: ABC, TDF |
| 9 | – | + | None |
| 10 | – | + | NNRTI: EFV; NRTI: 3TC, D4T |
| 11 | – | + | None |
*KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; FTC, emtricitabine; TDF, tenofovir; PI, protease inhibitor; ATV, atazanavir; RTV, ritonavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; EFV, Efavirenz; 3TC, lamivudine; NVP, nevirapine; AZT, azidothymidine; ABC, D4T, stavudine.
